Spray Drying: Solving solubility issues with amorphous solid dispersions

Posted: 3 September 2015 |

Amorphous solid dispersions (ASDs) are increasingly being used as a means of improving bioavailability of poorly water-soluble compounds in research and development, and spray drying technology has been recognised as one of the useful methods to generate ASDs.

Spray Drying: Solving solubility issues with amorphous solid dispersions

Although the application of spray drying for the production of amorphous solid dispersions in the drug discovery stage is still limited, amorphous solid dispersions prepared with a small-scale spray drying process can be an effective approach to deliver high doses of poorly water-soluble compounds and to enhance their plasma exposure in in vivo studies for early drug discovery efforts. This article reviews the application of this technology for the production of amorphous solid dispersions in a single process, and the use of small-scale spray dryers to produce amorphous solid dispersions as early preclinical formulations using only milligram quantities of drug substances.

Early preclinical formulations

It is estimated that 40 to 60% of drug compounds in today’s drug discovery phases exhibit poor aqueous solubility, and these compounds frequently have certain delivery limitations. Early preclinical formulations are developed for in vivo pharmacology, safety pharmacology and toxicology studies in drug discovery. The main purpose of these formulations is to obtain sufficient plasma exposure in in vivo studies for optimising, selecting and advancing compounds to the clinic. However, inadequate plasma exposure does not sufficiently provide safety margins surrounding the predicted efficacious dose in animal models.

Oral gavage is the most common route in animal dosing, and in general, solution formulations are preferred due to their simplicity, dose accuracy and dose flexibility. For poorly water-soluble compounds, enabling solution formulations with solubility enhancement using a co-solvent, cyclodextrin, surfactant, lipid-based product, or the combination formulations, are employed to yield improved plasma exposures. However, these enabling solution formulations often have limitations, such as poorly soluble compounds failing to reach target drug concentrations. Drug precipitation and vehicle-related side effects can also occur. These issues limit the amount of the poorly soluble compounds that can be administered to animals as a solution…

The rest of this article is restricted - login or subscribe free to access

european pharmaceutical review magazine cover issue 2 2018Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here


Related topics

Comments are closed.

Send this to a friend